Ideal for: VEGF inhibition studies, bone metastasis development, hypoxia and tumor progression
786-O is a hypertriploid renal cell carcinoma (RCC) cell line that was one of the first and most commonly used RCC cell lines established. 786-O cells have mutant Hippel-Lindau (VHL), which is the most common tumor suppressor mutation in clear cell RCC (ccRCC), occurring in up to 90% of ccRCC cases. 786-O cells also have altered hypoxia-induced factor (HIF) and vascular endothelia growth factor (VEGF) pathways. 786-O cells were used to demonstrate that VHL mutations are not sufficient to induce a hypoxic phenotype in RCC cells. The VHL gene was also found to play a distinct role in the HIF and VEGF signaling pathways in 786-O cells1.
786-O cells were isolated from a primary tumor sample, but they form tibial bone metastases in nude mice when injected directly into the tibia or into circulation via the cardiac ventricle. Additionally, 786-O cells express elevated levels of mesenchymal genes (eg vimentin), suggesting that xenografts of 786-O cells in the OncoRat could be used to study RCC metastasis in vivo.
768-O cells have homozygous p53, PTEN, and p16 (CDKN2A) mutations. Additionally, it expresses parathyroid hormone (PTH) like peptide. 786-O has proven useful in cancer stem cell studies and bone metastasis.
Enabling Case Study: 786-O Tumor Kinetics in OncoRat
The OncoRat demonstrated a 100% engraftment rate for the 786-O xenograft model, providing an ideal host for 786-O tumor biology.
786-O products & services
- Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
- Weekly or bi-weekly tumor sampling via fine need aspiration (FNA). For longitudinal evaluation of drug exposure, histology and gene expression.
- OncoRats off-the-shelf for engraftment at the customers facility.
- Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Molecular cancer. 2016;15(1):83-83.